Lv4
696 积分 2022-07-22 加入
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
1天前
已完结
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease
1天前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
9天前
已完结
A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial
9天前
已完结
Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention
10天前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
14天前
已完结
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus
14天前
已完结
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
17天前
已完结
The Photochemistry of the Future
23天前
已完结
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
28天前
已完结
皖公网安备34019202002308
